BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
금요일, 9월 25

Artelo Biosciences Inc

ARTLNASDAQ
Trade with Public
Trade with Public
$4.62
-0.55-10.73%
마지막 업데이트: Sep 25, 2:12 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교주식 보고서

Artelo Biosciences Earnings & Forecasts

Artelo Biosciences (ARTL) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

Quarterly Revenue (Billions)

Artelo Biosciences Guidance

Recent Earnings Results

MetricQ2 '26Q1 '26Q4 '25Q3 '25
Earnings Per Share (Non-GAAP)
Estimate—$-14.13$-42.39$-22.14
Actual$-8.01$-36.00$37.26$-107.19
Surprise—-154.8%+187.9%-384.1%
Revenue
Estimate————
Actual$0$0—$0
Surprise————

Earnings & Guidance News

PRO
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
Benzinga Newsdesk

PRO
Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share
Benzinga Newsdesk

PRO
Artelo Biosciences Q4 EPS $1.38 Beats $(1.57) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $(1.57) by 187.9 percent. This is a 119.66 percent increase over losses of $(7.02) per share
Benzinga Newsdesk

PRO
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(0.82) by 384.15 percent. This is a 89.05 percent decrease over losses of $(2.10) per share
Benzinga Newsdesk

Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results

Avi Kapoor

PRO
Artelo Biosciences Q2 EPS $(5.61) Misses $(4.19) Estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(5.61) per share which missed the analyst consensus estimate of $(4.19) by 33.89 percent. This is a 24.67 percent decrease over losses of $(4.50) per share
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved